The study reports on a longlasting comparative RT‐qPCR/dPCR monitoring of BCR‐ABL1 transcript levels in 142 CML patients having a median duration of TKI treatment and DMR of 8.3 years and 5.9 years, respectively. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.